

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application 16519 U.S. PTO Atty. Dkt.: 604-704

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date: December 23, 2003

Sir:

Attached for filing is the patent application of:

Inventor: BOLT et al

Entitled: HUMANIZED ANTI-CD3 SPECIFIC ANTIBODIES (AS AMENDED)

and including attachments as noted below:

Newly executed Declaration,  Copy of Declaration from prior application,  Abstract  
 Please delete the following inventors in the continuation/division/continuation-in-part application:

## Deleted persons:

29 pages of specification and claims (including 27 numbered claims), and  
7 sheets of accompanying drawing/s. Record the attached assignment to \_\_\_\_\_ and return to the undersigned.  
 Attached is a Power of Attorney. Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

Application Number	Country	Day/Month/Year Filed
9206422.9	United Kingdom	24 March 1992
PCT/GB92/01933		21 October 1992

, respectively, the entire content of which is hereby incorporated by reference in this application..  
 Certified copy(ies) of foreign application(s) is/are attached.  
 Certified copy(ies) filed on \_\_\_\_\_ in prior appln. no. \_\_\_\_\_ filed \_\_\_\_\_  
 This application claims the benefit of Provisional Application No. \_\_\_\_\_, filed \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.  
 This application is a  continuation/ division/ continuation-in-part of Application No. 08/478,684, filed June 7, 1995, which is a continuation of Application No. 07/988,925, filed November 8, 1993, the entire content of which is hereby incorporated by reference in this application.  
 Petition filed in prior application to extend its life to insure co-pendency.  
 The prior application is assigned to BTG International Limited, London, England.  
 It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached.  
 Applicant claims "small entity" status.  "Small entity" statement attached.  
 Please enter the attached preliminary amendment prior to calculation of filing fee:  
 Also attached:  Information Disclosure Statement;  Non-Publication Request;  Nucleotide and/or Amino Acid Sequence Submission;  Statement deleting Inventor(s) named in prior application;  Other:

**FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED**

Basic Filing Fee	\$	770.00
Total effective claims 27 - 20 (at least 20) = 7 x \$ 18.00	\$	126.00
Independent claims 1 - 3 (at least 3) = 0 x \$ 86.00	\$	0.00
If any proper multiple dependent claims now added for first time, add \$290.00 (ignore improper)	\$	0.00
	<b>SUBTOTAL</b>	\$ 896.00
If "small entity," then enter half (1/2) of subtotal and subtract		-\$( 0.00)
	<b>SECOND SUBTOTAL</b>	\$ 896.00
Assignment Recording Fee (\$40.00)		\$ 0.00
	<b>TOTAL FEE ENCLOSED</b>	\$ 896.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.  
The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140.  
A duplicate copy of this sheet is attached.

Correspondence Address:

Customer Number: **23117**

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

LCM:Ifm

NIXON &amp; VANDERHYE P.C.

By Atty: Leonard C. Mitchard, Reg. No. 29,009

Signature: 